FINFinance NO. ---
EQT Qiagen Takeover: €10.8bn Deal at a 40.3% Premium Explained
Qiagen's boards back the all-cash offer, with ADIA and CPP Investments as co-investors. It needs 50% plus one acceptances, an EGM vote and regulatory clearances, with closing expected in mid-2027.
Key takeaways
- Qiagen has agreed to a recommended all-cash takeover offer from EQT Private Equity at €46.50 per share, valuing the diagnostics group at about €10.8 billion ($12.1 billion) including net debt, according to the companies' joint announcement of 21 October 2026.
- The price is a 40.3% premium to Qiagen's Xetra close of €33.15 on 8 July 2026, the last trading day before reports of private equity interest.
- Luxinva, a subsidiary of the Abu Dhabi Investment Authority (ADIA), and CPP Investment Board Europe, a subsidiary of CPP Investments, are co-investors.
- The offer needs acceptances of 50% of shares plus one, approvals at an extraordinary general meeting (EGM), and merger-control and foreign-investment clearances. Closing is expected in mid-2027.
- Bloomberg News reported in July that EQT, Advent and KKR were studying bids. Only EQT has announced an agreement.
What are the EQT Qiagen takeover terms?
The EQT Qiagen takeover values the group at about €10.8 billion ($12.1 billion) including net debt. EQT Private Equity will offer €46.50 in cash per share, a 40.3% premium to Qiagen's Xetra close of €33.15 on 8 July 2026, before reports of private equity interest. For how a rival buyout firm is faring, see Blackstone's Q3 2026 earnings.
Both Qiagen boards, the Supervisory Board and the Managing Board, unanimously approved the business combination agreement. According to the release, they intend to recommend that shareholders tender their shares and vote for the post-closing measures. The formal recommendation will follow once the offer document is published.
The companies said EQT has committed equity and debt financing to cover the full offer and transaction costs, and that the offer has no financing condition. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are lead arrangers and bookrunners for the debt.
Deal terms at a glance
| Item | Detail | Source |
|---|---|---|
| Offer price | €46.50 per share, cash | Joint release, 21 Oct 2026 |
| Unaffected price | €33.15 (Xetra close, 8 Jul 2026) | Joint release |
| Premium to unaffected close | 40.3% | Joint release |
| Premium to 3-month VWAP (€31.66) | 46.9% | Joint release |
| Enterprise value | About €10.8bn (about $12.1bn), including about $1.1bn net debt | Joint release |
| Minimum acceptance | 50% of outstanding share capital plus one share | Joint release |
| Possible interim dividend | Up to $0.47 per share if closing is delayed beyond 10 months by pending approvals; would not reduce the offer price | Joint release |
| Expected closing | Mid-2027 | Joint release |
| QGEN close, NYSE, 21 Oct 2026 | $50.00, up 2.25% (data as of 20:00 UTC, 21 Oct 2026) | RTTNews |
Why is the premium measured from July?
The 40.3% premium is not measured against the share price on the day of the announcement. It is measured against the "unaffected" price of 8 July 2026, the last trading day before reports of buyout interest moved the stock.
On 9 July, Bloomberg News reported that EQT, Advent and KKR were exploring a takeover. It said some suitors were considering an offer of at least $50 per share. Reuters, which said it could not immediately verify the report, wrote that Qiagen's Frankfurt shares rose at least 10% that day. At the time Qiagen and KKR declined to comment, and Advent and EQT were not immediately available.
That is why the gap between the offer and the latest trading price is much smaller than the headline premium. On 21 October, the day of the announcement, Qiagen's New York shares closed at $50.00, up 2.25%, according to RTTNews.
What happened to the other suitors?
No rival offer has been announced. European Biotechnology noted that earlier speculation had pointed to a possible contest between EQT and KKR. Neither KKR nor Advent has publicly said whether it made a bid. Qiagen had said earlier in 2026 that it was reviewing strategic options with Moelis and Goldman Sachs. Bloomberg had first reported in January that a sale was among the options.
How the offer process will work
Qiagen is a Dutch holding company with a German listing, so the process runs under several rulebooks. Germany's financial regulator BaFin must approve the offer document before it is published. Publication starts the acceptance period. The bidder will also file a Schedule TO tender offer statement with the SEC for U.S. holders.
Qiagen will hold an EGM during the initial acceptance period. Shareholders will vote on the "post-closing measures", a set of steps that lets the buyer take full ownership and remove the shares from the Frankfurt Stock Exchange and NYSE. If at least 80% of votes cast approve, the boards will take a formal "implementation decision". If support is lower, the release says the boards may still go ahead if they judge it to be in Qiagen's best interest and the measures have substantial majority support. In that judgement they may weigh turnout and how long shareholders have held their shares.
The release warns that shareholders who do not tender will receive a cash distribution equal to the offer price, but after withholding taxes. That amount may be less than they would receive by tendering.
Why is private equity buying a listed diagnostics company?
Qiagen sells sample-preparation kits, instruments and molecular tests used by hospitals, laboratories and drug developers. In 2025 it reported net sales of $2.09 billion, up 5% at constant exchange rates. Its adjusted operating margin was 29.5%, according to its full-year results filed with the SEC in February.
| Qiagen FY2025 metric | Value | Growth (CER) |
|---|---|---|
| Net sales | $2.09bn | +5% |
| Diagnostic solutions | $803m | +6% |
| Sample technologies | $661m | +2% |
| QuantiFERON (TB testing) | $503m | +10% |
| QIAstat-Dx (syndromic testing) | $139m | +24% |
| Adjusted operating margin | 29.5% | up from 28.7% |
Source: Qiagen Q4 and full-year 2025 results, 4 February 2026. For 2026, Qiagen guided to net sales growth of at least 5% at constant currency.
Steady, recurring revenue from consumables and high margins are features buyout firms often look for, because they can support the debt used to finance a deal. The companies give their own reasons. Qiagen's boards said private ownership would make long-term investment easier and give management more flexibility. They said they consider the offer the best path for the next growth phase, including compared with staying listed. Chief executive Jonathan M. Pratt said that under private ownership "we can move faster". Chief financial officer Roland Sackers described the deal as providing shareholders "an attractive premium".
EQT pointed to its healthcare record, which includes current or former holdings such as Galderma, Parexel, Aldevron, SPT Labtech, Dako and HemoCue. Matteo Thun-Hohenstein, a partner at EQT, called Qiagen "an outstanding global leader in the life science tools and diagnostics market". Michael Bauer, EQT's global co-head of healthcare, described it as a landmark transaction for the firm.
EQT has made commitments on strategy, brands, operational footprint, research and development, employees and financing. Qiagen will keep its name and will run independently under its current management until closing. The release does not announce job cuts, site changes or a new headquarters.
What it means
For Qiagen shareholders, the main questions are whether enough holders tender to reach the 50%-plus-one threshold, and whether the post-closing measures win strong support at the EGM. A rival offer is another variable. None has been announced.
For regulators, the deal still needs merger-control and foreign-investment clearances. The mid-2027 target shows how long that review is expected to take. The interim-dividend clause covers a longer delay. If the deal closes, Qiagen will leave both the Frankfurt and New York exchanges.
The next milestones are BaFin's approval and publication of the offer document, the start of the acceptance period, and the EGM date. Readers can follow the wider market backdrop in our Europe stocks daily brief and US stocks daily brief. Other recent deal coverage includes Bose's acquisition of Skullcandy and what Elon Musk confirmed about a Tesla-SpaceX merger.
Frequently asked questions
How much is EQT paying for Qiagen?
EQT Private Equity's offer is €46.50 per share in cash, valuing Qiagen at about €10.8 billion ($12.1 billion) in enterprise value, including about $1.1 billion of net debt, according to the joint announcement of 21 October 2026.
When will the EQT takeover of Qiagen close?
The companies expect closing in mid-2027, subject to a minimum acceptance of 50% of shares plus one, resolutions at an extraordinary general meeting, and merger-control and foreign-investment clearances.
Will Qiagen be delisted?
Yes, if the deal completes. After the post-closing measures take effect, Qiagen shares are to be delisted from the Frankfurt Stock Exchange and the New York Stock Exchange.
Who are EQT's partners in the Qiagen deal?
Luxinva, a subsidiary of the Abu Dhabi Investment Authority, and CPP Investment Board Europe, a subsidiary of CPP Investments, are co-investors alongside the EQT XI fund.
Sources
- Qiagen and EQT Private Equity joint announcement, Exhibit 99.1 (SEC filing, 21 Oct 2026)
- Business Wire via Morningstar: Qiagen and EQT Private Equity announce agreement (21 Oct 2026)
- Qiagen Q4 and full-year 2025 results (SEC Form 6-K, 4 Feb 2026)
- RTTNews: Qiagen agrees to EQT takeover offer at €46.50 per share
- European Biotechnology: Qiagen agrees to go private with €10.8bn takeover by EQT
- Reuters via M&A Critique: EQT, Advent, KKR explore takeover of Qiagen, Bloomberg News reports (Jul 2026)
- Bloomberg: Qiagen is said to attract early interest from EQT, Advent (Jul 2026)
This article is for information only and is not investment advice.
